phase 2_completion
saveXijing Hospital — pertuzumab + trastuzumab (Phase II Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Triple-Negative Breast Cancer (TNBC)
Data sources
globaldata
Found something off?
comments(0)
5-min edit window · permanent after that